The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

Inclusion Criteria: * Confirmed SARS-CoV-2 infection by PCR, documented positive test, or clinician diagnosis * Meeting CDC criteria for Post-COVID Conditions (Long COVID) as the presence of new, returning, or ongoing symptoms ≥4 weeks after confirmed SARS-CoV-2 infection * Hamilton Depression Rating Scale (HAMD-21) score ≥18 at baseline * Stable antidepressant treatment for ≥4 weeks or no current antidepressant use; and * Ability to provide written informed consent Exclusion Criteria: * Current or past six-month diagnosis of psychotic disorder, bipolar disorder, substance use disorder, or other major psychiatric conditions based on ICD-10 or DSM-5 criteria * Significant neurological or medical comorbidities (eg, epilepsy, traumatic brain injury, autoimmune disease, cancer), acute infections, or clinically significant laboratory abnormalities * Regular use of SPM or EPA supplementation \>0·5 g/day * Known allergy or intolerance to omega-3 fatty acids or SPMs; and * Requirement for inpatient psychiatric care due to acute suicide risk